Mr. Miguel Martin reports

AURORA CANNABIS PROVIDES BUSINESS UPDATE; ACCRETIVE ACQUISITION OF SAFARI FLOWER COMPANY AND LEADING EUROPEAN PERFORMANCE EXPECTED TO FUEL INTERNATIONAL GROWTH IN THE FISCAL SECOND QUARTER 2027 AND BEYOND

Aurora Cannabis Inc. has provided a business update, highlighting the expected additional benefits of the Safari Flower Company acquisition, has continued strong performance in key high-margin international markets and has reaffirmed its fiscal year 2027 second quarter guidance.

"We remain focused and confident in executing our global growth strategy that, at its core, leverages our leadership position as one of the world's largest indoor EU-GMP certified producers and are excited by the continued momentum we are generating in key international markets," said Miguel Martin, executive chairman and chief executive officer of Aurora.

"We are building real value in global medical cannabis markets where Aurora has earned a stellar reputation by investing in infrastructure, scientific excellence and regulatory expertise to maximize opportunities in the industry's most attractive, durable and profitable segment. Our leading market share in Canada, Europe, Australia and New Zealand clearly demonstrates that Aurora's high-quality medical cannabis products are a preferred choice for physicians and patients alike. We are also ready and able to export to other countries as regulatory environments continue to open," added Mr. Martin.

"The accretive acquisition of Safari Flower Company is adding critical EU-GMP capacity, and, together with our established internal supply network and the recent acquisitions in the U.K., we have built a consistent and reliable availability of high-quality medical cannabis products to meet growing patient demand in the estimated $9-billion market for global medical cannabis," concluded Mr. Martin.

Aurora reaffirms its fiscal year 2027 Q2 guidance for sequential growth in quarterly net revenue and adjusted earnings before interest, taxes, depreciation and amortization. This outlook reflects the strategic steps taken to focus exclusively on global medical cannabis. Aurora's growth is further supported by a strong balance sheet with $149-million in cash as of June 30, 2026, and no debt, noting that the ATM program will only be used when the board determines it is in the best interest of the company to do so. Aurora will continue to invest over the next several quarters in its international business to support growth in key markets and position the company to create greater shareholder value.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class good-manufacturing-practice-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

Aurora's common shares trade on Nasdaq and the Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.